1.
The efficacy of voxelotor, 900 mg in patients with sickle cell anemia: a meta-analysis of the randomized controlled trials
Tanriverdi LH, Sarici A, Erkurt MA, Parlakpinar H
International journal of clinical practice. 2020;:e13967
Abstract
Sickle cell anemia (SCA) is an autosomal recessive disease caused by a mutation in the gene that codes the β-globin chain of hemoglobin. The abnormal hemoglobin (hemoglobin S) can polymerize when deoxygenated, changing the physical properties of the red cells (which deform to a sickle shape, hence the name) and damages cell membranes.(1) Sickle cell anemia can lead to a variety of signs and symptoms namely vaso-occlusive attacks (presenting as pain, tissue hypoxia, necrosis, and organ damage), acute chest syndrome, hemolytic crisis, and primary and secondary stroke.